Hikone, Japan

Munetsugu Morimoto


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Munetsugu Morimoto: Innovator in Antibacterial Compounds

Introduction

Munetsugu Morimoto is a notable inventor based in Hikone, Japan. He is recognized for his contributions to the field of medicinal chemistry, particularly in the development of antibacterial compounds. His innovative work has led to advancements in the treatment of infections, showcasing the importance of research in pharmaceuticals.

Latest Patents

Morimoto holds a patent for a 1-methylcarbapenem derivative, which is a compound that exhibits significant antibacterial activity. The patent describes a 1-methylcarbapenem compound represented by a specific formula, where various groups can be substituted to enhance its effectiveness. This compound is not only a breakthrough in antibacterial treatment but also serves as a preventive measure against infections. The patent highlights the potential of these compounds as pharmacologically acceptable salts or derivatives.

Career Highlights

Throughout his career, Munetsugu Morimoto has made significant strides in the pharmaceutical industry. He is currently associated with Sankyo Company, Limited, where he continues to contribute to innovative research and development. His work has been instrumental in advancing the understanding and application of antibacterial agents.

Collaborations

Morimoto has collaborated with esteemed colleagues, including Isao Kawamoto and Katsuya Ishikawa. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their research.

Conclusion

Munetsugu Morimoto's contributions to the field of antibacterial compounds exemplify the impact of innovation in medicine. His patent for 1-methylcarbapenem derivatives represents a significant advancement in the fight against infections. Through his work at Sankyo Company, Limited, and collaborations with fellow researchers, Morimoto continues to pave the way for future developments in pharmaceutical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…